Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04094363
Recruitment Status : Not yet recruiting
First Posted : September 18, 2019
Last Update Posted : September 18, 2019
Sponsor:
Collaborator:
ICON plc
Information provided by (Responsible Party):
RAI Services Company

Brief Summary:
This is a randomized, open-label, crossover study designed to evaluate elements of abuse liability (AL) including subjective effects, plasma nicotine uptake, and physiological measures during and following ad libitum use of the investigational products (IPs) by healthy subjects.

Condition or disease Intervention/treatment Phase
Smoking Tobacco Smoking Tobacco Use Other: Product A Other: Product B Other: Product C Other: Product D Not Applicable

Detailed Description:

The study will recruit smokers of combustible cigarettes.

Potential subjects will complete a pre-screening interview and a Screening Visit to assess their eligibility within 45 days prior to enrollment.

Starting on Day 1, eligible smokers will be confined at the clinical site for 9 days. Subjects will participate in four separate Test Sessions for AL assessment, one for each IP. Each Test Session will last for approximately 4 hours during and following IP use. Subjects will be randomized to use one IP in each Test Session: Usual Brand (UB) combustible cigarettes, nicotine gum, and 2 Electronic Nicotine Delivery Systems (ENDS).

For approximately a day and a half prior to each respective Test Session, IP will be dispensed for ad libitum use for product familiarization.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: CSD190202: A Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems
Estimated Study Start Date : September 18, 2019
Estimated Primary Completion Date : December 18, 2019
Estimated Study Completion Date : December 18, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: E-Cigarettes

Arm Intervention/treatment
Experimental: Product usage order ABCD
Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
Other: Product A
Usual Brand, filtered combustible cigarette

Other: Product B
CSD1902-11, an electronic nicotine delivery system

Other: Product C
CSD1902-21, an electronic nicotine delivery system

Other: Product D
4mg Nicotine gum

Experimental: Product usage order BDAC
Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
Other: Product A
Usual Brand, filtered combustible cigarette

Other: Product B
CSD1902-11, an electronic nicotine delivery system

Other: Product C
CSD1902-21, an electronic nicotine delivery system

Other: Product D
4mg Nicotine gum

Experimental: Product usage order CADB
Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
Other: Product A
Usual Brand, filtered combustible cigarette

Other: Product B
CSD1902-11, an electronic nicotine delivery system

Other: Product C
CSD1902-21, an electronic nicotine delivery system

Other: Product D
4mg Nicotine gum

Experimental: Product usage order DCBA
Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
Other: Product A
Usual Brand, filtered combustible cigarette

Other: Product B
CSD1902-11, an electronic nicotine delivery system

Other: Product C
CSD1902-21, an electronic nicotine delivery system

Other: Product D
4mg Nicotine gum




Primary Outcome Measures :
  1. AUECPL 10-240 [ Time Frame: 3, 5, 10, 15, 30, 45, 60, 90, 180, and 240 minutes ]
    Area under the product liking (PL) NRS score-versus-time curve from 10 minutes to 240 minutes after the start of investigational product (IP) use.

  2. Emax PL [ Time Frame: 3, 5, 10, 15, 30, 45, 60, 90, 180, and 240 minutes ]
    Maximum response for product effects with regards to PL score after the start of IP use.

  3. Eoverall IUA [ Time Frame: 240 minutes ]
    Overall intent to use again (IUA), measured at 240 minutes after the start of IP use.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.
  2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.
  3. Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.
  4. Positive urine cotinine test at Screening.
  5. Smokes only combustible, filtered, non-menthol, 83 mm to 100 mm in length.
  6. Agrees to smoke same UB combustible cigarette throughout the study period. UB combustible cigarette is defined as the cigarette brand style currently smoked most frequently by the subject.
  7. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Principal Investigator (PI).
  8. Response at Screening to Fagerström Test for Nicotine Dependence (FTND) Question 1 ("How soon after you wake up do you smoke your first cigarette?") is either "Within 5 minutes" or "6-30 minutes."
  9. Willing to use UB combustible cigarette, ENDS, and Nicorette gum during the study period.
  10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each Test Session.
  11. Females must be willing to use a form of contraception acceptable to the PI from the time of signing informed consent until End-of-Study.
  12. Agrees to in-clinic confinement of 9 days and 8 nights.

Exclusion Criteria:

  1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study subject unsuitable to participate in this clinical study.
  2. History, presence of, or clinical laboratory test results indicating diabetes.
  3. Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg, measured after being seated for five minutes.
  4. Weight of ≤ 110 pounds.
  5. Hemoglobin level is < 12.5 for females or <13.0 for males g/dL at Screening.
  6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion pending approval from the Medical Monitor.
  7. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
  8. Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.
  9. Use of an ENDS or other tobacco or nicotine-containing product (e.g., lozenges, moist snuff) within (≤) 30 days prior to Screening.
  10. Use of any medication or substance that aids in smoking cessation, including but not limited to any Nicotine Replacement Therapy (NRT) (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to the signing of informed consent.
  11. History or presence of bleeding or clotting disorders.
  12. Any use of anticoagulants or aspirin (≥ 325 mg/day).
  13. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent.
  14. Plasma donation within (≤) 7 days prior to the signing of informed consent.
  15. Participation in another clinical trial within (≤) 30 days prior to the signing of informed consent. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.
  16. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
  17. Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
  18. A positive urine drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening or Day 1.
  19. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous attempt within (≤) 30 days prior to the signing of the ICF.
  20. Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol breathalyzer result at Screening or Day 1.
  21. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.
  22. Determined by the PI to be inappropriate for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04094363


Contacts
Layout table for location contacts
Contact: John Darnell 336-741-0386 darnelj2@rjrt.com
Contact: Kristen Prevette 336-741-1873 prevetk1@rjrt.com

Locations
Layout table for location information
United States, Tennessee
New Orleans Center for Clinical Research (NOCCR) Not yet recruiting
Knoxville, Tennessee, United States, 37920
Principal Investigator: William Smith, MD         
United States, Texas
ICON Clinical Research Not yet recruiting
San Antonio, Texas, United States, 78209
Principal Investigator: Cassandra Key, MD         
Sponsors and Collaborators
RAI Services Company
ICON plc
Investigators
Layout table for investigator information
Study Director: Jason Hong, MD RAIS

Layout table for additonal information
Responsible Party: RAI Services Company
ClinicalTrials.gov Identifier: NCT04094363     History of Changes
Other Study ID Numbers: CSD190202
First Posted: September 18, 2019    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action